Envestnet Asset Management Inc. Has $19.16 Million Position in Hologic, Inc. $HOLX

Envestnet Asset Management Inc. raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 283,934 shares of the medical equipment provider’s stock after purchasing an additional 11,837 shares during the period. Envestnet Asset Management Inc. owned 0.13% of Hologic worth $19,163,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of HOLX. Winnow Wealth LLC acquired a new position in Hologic in the 3rd quarter valued at $26,000. Caitong International Asset Management Co. Ltd grew its position in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 273 shares during the last quarter. Root Financial Partners LLC bought a new position in shares of Hologic in the third quarter worth about $27,000. SJS Investment Consulting Inc. lifted its position in shares of Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 362 shares during the last quarter. Finally, Loomis Sayles & Co. L P acquired a new position in shares of Hologic during the 2nd quarter worth about $33,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HOLX has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and cut their target price for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Finally, Morgan Stanley increased their target price on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 11th. Two equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Stock Performance

NASDAQ HOLX opened at $75.04 on Friday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $75.36. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The stock has a market cap of $16.75 billion, a P/E ratio of 31.27, a PEG ratio of 2.24 and a beta of 0.72. The company’s 50-day simple moving average is $74.89 and its 200 day simple moving average is $71.59.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the firm posted $0.87 earnings per share. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.